Lee Feander is a Senior Director with Alvarez & Marsal Healthcare and Life Sciences practice in London. He specializes in life sciences supply chain, strategy development, process improvement and transformation. Mr. Feander has worked with clients across a range of industries, including pharmaceuticals, medical technology, the National Health Service, regulators and private equity firms.
With more than 15 years of experience working in health sectors, Mr. Feander has worked with Roche to define supply chain strategies for cell and gene therapies; yielded a 15 percent reduction in cost logistics for Biogen; and worked with Sandoz to identify $300 million from moving production to low-cost countries and closing facilities.
Mr. Feander’s notable assignments include carving out and transferring $4 billion from Alcon to Novartis across 130 countries; delivering a global cost reduction program for AstraZeneca, including savings totaling 34 million euros; and identifying 20 percent savings on procurement costs for J&J.
Prior to joining A&M, Mr. Feander spent over two years with Deloitte in London, where he most recently served as Director. Previously, he served as Senior Manager with A.T. Kearney. He also held a leadership position with GE Healthcare.
Mr. Feander earned a bachelor’s degree in mechanical engineering from the University of Warwick and a master’s degree in manufacturing and management from the University of Cambridge.
A&M’s EMEA Healthcare & Life Sciences and Ops & Supply Chain teams have shared their predictions for CDMOs in 2030, and their perspectives on what CDMOs should be addressing now to achieve success in the future.
How pharmaceutical companies can take learnings from high-growth technology businesses to continuously optimise their footprint and pay down footprint design debt
As global challenges continue, asset-light pharmaceutical companies will remain under increased pressure for the rest of 2022 and beyond. How can asset-light companies create value in a disrupted market? A&M shares 5-value levers for asset-light pharmaceutical businesses.
Latest insightsThe latest insights from Lee Feander's team
Discover the state of infrastructure investment, as uncertain markets adjust to higher interest rates and cost of capital, and supply chain disruptions.
